Jiao Zhang1, Baoguo Li1, Qing Yang2, Pengyu Zhang3, Haitao Wang4. 1. Department of Interventional Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Research Group of Evidence-based Clinical Oncology, Tianjin Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin. 2. Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Department of Urologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin. 3. Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Department of Laboratory Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 4. Department of Interventional Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Research Group of Evidence-based Clinical Oncology, Tianjin Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin wht1972@126.com.
Abstract
OBJECTIVE: The prognostic significance of Aurora kinase A expression in cancer patients is currently under debate. Here, we conducted the first comprehensive meta-analysis of the prognostic relevance of Aurora kinase A associated with survival in solid tumors. METHODS: Pubmed was searched for studies evaluating the Aurora kinase A expression and survival in solid tumors through 10 October 2014. The main outcome analyzed was overall survival and secondary outcomes were progression-free survival, disease-free survival and cancer-specific survival. Pooled hazard ratio and 95% confidence intervals were calculated to assess the association. Subgroup and sensitivity analyses were also conducted. RESULTS: Thirty-nine eligible studies enrolling 5523 patients were identified. The high Aurora kinase A expression level was significantly associated with shorter overall survival (hazard ratio = 2.31; 95% confidence interval, 1.81-2.95). Further subgroup analyses showed that our results were stable irrespective of the disease sites, stages and methods of Aurora kinase A expression. The high Aurora kinase A expression level was also associated with progression-free survival (hazard ratio = 2.68; 95% confidence interval, 1.96-3.69), disease-free survival (hazard ratio = 1.91; 95% confidence interval, 1.45-2.51) and cancer-specific survival (hazard ratio = 2.13; 95% confidence interval, 1.38-3.29). CONCLUSIONS: Our present meta-analysis indicates that the Aurora kinase A is an effective prognosticator in solid tumors patients. Further studies are required to explore the clinical utility of Aurora kinase A in solid tumor.
OBJECTIVE: The prognostic significance of Aurora kinase A expression in cancerpatients is currently under debate. Here, we conducted the first comprehensive meta-analysis of the prognostic relevance of Aurora kinase A associated with survival in solid tumors. METHODS: Pubmed was searched for studies evaluating the Aurora kinase A expression and survival in solid tumors through 10 October 2014. The main outcome analyzed was overall survival and secondary outcomes were progression-free survival, disease-free survival and cancer-specific survival. Pooled hazard ratio and 95% confidence intervals were calculated to assess the association. Subgroup and sensitivity analyses were also conducted. RESULTS: Thirty-nine eligible studies enrolling 5523 patients were identified. The high Aurora kinase A expression level was significantly associated with shorter overall survival (hazard ratio = 2.31; 95% confidence interval, 1.81-2.95). Further subgroup analyses showed that our results were stable irrespective of the disease sites, stages and methods of Aurora kinase A expression. The high Aurora kinase A expression level was also associated with progression-free survival (hazard ratio = 2.68; 95% confidence interval, 1.96-3.69), disease-free survival (hazard ratio = 1.91; 95% confidence interval, 1.45-2.51) and cancer-specific survival (hazard ratio = 2.13; 95% confidence interval, 1.38-3.29). CONCLUSIONS: Our present meta-analysis indicates that the Aurora kinase A is an effective prognosticator in solid tumorspatients. Further studies are required to explore the clinical utility of Aurora kinase A in solid tumor.
Authors: Hyun Min Koh; Bo Geun Jang; Chang Lim Hyun; Young Sill Kim; Jin Won Hyun; Weon Young Chang; Young Hee Maeng Journal: J Pathol Transl Med Date: 2016-12-25
Authors: Po-Jen Yang; Ming-Ju Hsieh; Chun-I Lee; Chi-Hua Yen; Hsiang-Ling Wang; Whei-Ling Chiang; Tu-Chen Liu; Thomas Chang-Yao Tsao; Chia-Yi Lee; Shun-Fa Yang Journal: Int J Environ Res Public Health Date: 2020-10-08 Impact factor: 3.390
Authors: Simone Punt; Shruti Malu; Jodi A McKenzie; Soraya Zorro Manrique; Elien M Doorduijn; Rina M Mbofung; Leila Williams; Deborah A Silverman; Emily L Ashkin; Ana Lucía Dominguez; Zhe Wang; Jie Qing Chen; Sourindra N Maiti; Trang N Tieu; Chengwen Liu; Chunyu Xu; Marie-Andrée Forget; Cara Haymaker; Jahan S Khalili; Nikunj Satani; Florian Muller; Laurence J N Cooper; Willem W Overwijk; Rodabe N Amaria; Chantale Bernatchez; Timothy P Heffernan; Weiyi Peng; Jason Roszik; Patrick Hwu Journal: Cancer Immunol Immunother Date: 2020-10-29 Impact factor: 6.968